These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 16159415)
1. Current status of mammalian target of rapamycin inhibitors in lung cancer. Gómez-Martín C; Rubio-Viqueira B; Hidalgo M Clin Lung Cancer; 2005 Sep; 7 Suppl 1():S13-8. PubMed ID: 16159415 [TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin: a new molecular target for breast cancer. Mita MM; Mita A; Rowinsky EK Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941 [TBL] [Abstract][Full Text] [Related]
3. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Smolewski P Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804 [TBL] [Abstract][Full Text] [Related]
4. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms. Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340 [TBL] [Abstract][Full Text] [Related]
5. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051 [TBL] [Abstract][Full Text] [Related]
6. Targeting mTOR for cancer treatment. Rubio-Viqueira B; Hidalgo M Adv Exp Med Biol; 2006; 587():309-27. PubMed ID: 17163174 [TBL] [Abstract][Full Text] [Related]
8. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway. Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281 [TBL] [Abstract][Full Text] [Related]
9. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application. Bertoni E; Salvadori M J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600 [TBL] [Abstract][Full Text] [Related]
10. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Rao RD; Mladek AC; Lamont JD; Goble JM; Erlichman C; James CD; Sarkaria JN Neoplasia; 2005 Oct; 7(10):921-9. PubMed ID: 16242075 [TBL] [Abstract][Full Text] [Related]
11. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Han S; Khuri FR; Roman J Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245 [TBL] [Abstract][Full Text] [Related]
12. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Hidalgo M; Rowinsky EK Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655 [TBL] [Abstract][Full Text] [Related]
13. Assessment of cell-signaling pathways in the regulation of mammalian target of rapamycin (mTOR) by amino acids in rat adipocytes. Pham PT; Heydrick SJ; Fox HL; Kimball SR; Jefferson LS; Lynch CJ J Cell Biochem; 2000 Sep; 79(3):427-41. PubMed ID: 10972980 [TBL] [Abstract][Full Text] [Related]
14. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain. Yu J; Henske EP Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601 [TBL] [Abstract][Full Text] [Related]
15. The role of targeting mammalian target of rapamycin in lung cancer. Pal SK; Figlin RA; Reckamp KL Clin Lung Cancer; 2008 Nov; 9(6):340-5. PubMed ID: 19073516 [TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Gibbons JJ; Abraham RT; Yu K Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098 [TBL] [Abstract][Full Text] [Related]
17. Determinants of rapamycin sensitivity in breast cancer cells. Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980 [TBL] [Abstract][Full Text] [Related]
18. Targeting mTOR for cancer treatment. Rubio-Viqueira B; Hidalgo M Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020 [TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds. Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575 [TBL] [Abstract][Full Text] [Related]